Lineage Cell Therapeutics, Inc. (LCTX)
NYSEAMERICAN: LCTX · Real-Time Price · USD
0.4695
-0.0205 (-4.18%)
Mar 31, 2025, 9:30 AM EST - Market open
Lineage Cell Therapeutics Stock Forecast
LCTX's stock price has decreased by -68.28% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Lineage Cell Therapeutics stock have an average target of 4.20, with a low estimate of 2.00 and a high estimate of 9.00. The average target predicts an increase of 794.57% from the current stock price of 0.47.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Lineage Cell Therapeutics stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 3 | 3 | 4 | 4 | 5 |
| Buy | 1 | 1 | 1 | 1 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 4 | 4 | 5 | 4 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| B. Riley Securities | B. Riley Securities | Strong Buy Maintains $4 → $3 | Strong Buy | Maintains | $4 → $3 | +538.98% | Mar 14, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $2 | Strong Buy | Maintains | $2 | +325.99% | Mar 11, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $9 | Strong Buy | Reiterates | $9 | +1,816.93% | Mar 11, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $9 | Strong Buy | Reiterates | $9 | +1,816.93% | Feb 11, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $3 → $2 | Strong Buy | Maintains | $3 → $2 | +325.99% | Feb 11, 2025 |
Financial Forecast
Revenue This Year
11.88M
from 9.50M
Increased by 25.10%
Revenue Next Year
16.12M
from 11.88M
Increased by 35.67%
EPS This Year
-0.09
from -0.09
EPS Next Year
-0.05
from -0.09
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 26.7M | 38.0M | 194.0M | ||
| Avg | 11.9M | 16.1M | 43.1M | ||
| Low | 3.3M | n/a | 3.3M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 180.8% | 219.9% | 1,103.0% | ||
| Avg | 25.1% | 35.7% | 167.5% | ||
| Low | -65.5% | - | -79.6% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.01 | 0.03 | -0.05 | ||
| Avg | -0.09 | -0.05 | -0.09 | ||
| Low | -0.15 | -0.15 | -0.12 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.